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1 Frank Reidy Research Center for Bioelectrics, Old Dominion University, Norfolk, VA, United States, 2 Department of
Microbiology & Immunology, Virginia Commonwealth University, Richmond, VA, United States, 3 Department of Medical
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Interleukin 15 (IL-15) has been evaluated as a potential treatment for solid tumors in clinical
trials, but the effectiveness of systemic IL-15 administration as a monotherapy has not
been realized. IL-15 receptor alpha (IL-15Ra) can stabilize IL-15 and enhance its
bioactivity. The goal of this study was to examine the activity of IL-15/IL-15Ra complex
(IL-15cx) to CD8+ T cells and evaluate its potential efficacy in murine breast cancer
models. The antitumor efficacy was studied in mouse mammary carcinoma models (Her2/
neu transgenic and 4T1-luc mammary cancers) treated with systemic recombinant
protein with/without the depletion of myeloid-derived suppressor cells or intra-tumoral
gene electrotransfer (GET). IL-15cx shows superior in vivo bioactivity to expand CD8 T
cells in comparison to an equimolar single chain IL-15. T-bet is partially involved in CD8 T
cell expansion ex vivo and in vivo due to IL-15 or IL-15cx. Intraperitoneal administration of
IL-15cx results in a moderate inhibition of breast cancer growth that is associated with an
increase in the frequency of cytotoxic CD8 T cells and the improvement of their function.
The depletion of myeloid-derived suppressor cells (MDSCs) has no impact on mouse
breast cancer growth. IL-15cx treatment diminishes MDSCs in murine tumors. However,
it also antagonizes the effects of anti-Gr-1 depleting antibodies. Intratumoral GET with
plasmid IL-15/IL-15Ra leads to a long-term survival benefit in 4T1 mammary carcinoma
model. An early increase of local cytotoxic cells correlates with GET treatment and an
increase of long-term memory T cells results from animals with complete tumor
regression. Systemic and local administration of IL-15cx shows two distinct therapeutic
responses, a moderate tumor growth inhibition or heterogeneous tumor regressions with
survival improvement. Further studies are warranted to improve the efficacy of IL-15cx as
an immunotherapy for breast cancer.
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A major breakthrough in cancer therapy is immune checkpoint
inhibitor (CPI)-based immunotherapy which has been approved
by the FDA for the treatment of multiple types of cancers (1).
However, some types of cancer are largely resistant to this
powerful immunotherapy. Resistance is typically related to the
immunogenicity of the tumor. One of these poorly immunogenic
tumors is breast cancer with response rates of only 0%–18.5% to
CPI therapy alone (2–4). Atezolizumab, an anti-PD-L1 antibody is
the first checkpoint inhibitor approved by FDA in combination
with chemotherapy to treat triple-negative and PD-L1 positive
metastatic breast cancer. Triple negative breast cancer only
accounts for approximately 20% of all breast cancer cases. PD-
L1 is expressed mainly on tumor-infiltrating immune cells in
roughly 41% of patients with triple negative breast cancer (5).
Considering these two percentages together, there are only a small
subset of breast cancer patients who would benefit from this
combination therapy. Other immunotherapeutic strategies and
combination approaches are needed to improve the therapeutic
efficacy and broaden its indications for a large patient population.
Interleukin 15 (IL-15) is a pleiotropic cytokine, which was
originally discovered by Drs. Waldmann and Grabstein’s groups
(6, 7). IL-15 is considered superior to IL-2 for cancer
immunotherapy due to its strong bioactivity in improving CD8+
T and natural killer (NK) cell survival, proliferation and cytotoxic
function (8). It also delivers its function without activating
regulatory T cells (Tregs) (9) and mediating activation-induced
cell death of effector cytotoxic T cells (10). IL-15 has been studied
in clinical trials as a potential treatment for various solid tumors;
however, its systemic administration has not been demonstrated to
be an effective monotherapy (11–13). In its monomeric form, IL-15
has a very short half-life requiring continuous intravenous infusion
(14). A significant discovery in the IL-15 immunobiological
research is the trans-presentation of IL-15 via pre-associated IL-
15/IL-15 receptor alpha (IL-15Ra) (15–17). By taking advantage of
this mechanism, several IL-15 superagonist fusion proteins and IL-
15/IL-15Ra complex (IL-15cx) have been generated and studied in
animal models and clinical trials (18). These IL-15 superagonists
exhibit prolonged half-lives and an increased potent bioactivity to
T cells andNK cells. IL-15cx or IL-15cx trans-presenting cells show
superior bioactivity and antitumor efficacy to IL-15 monomer in
multiple preclinical tumor models (18–20). IL-15cx has been
reported to effectively treat murine melanoma and pancreatic
tumors (21–23). There are no studies on the therapeutic efficacy
of IL-15cx treatment for breast cancer whereas an IL-15
superagonist mutant (IL-15N72D) and dimeric IL-15RaSushi-Fc
fusion protein or N803 has been reported to prolong the survival of
breast cancer bearing mice with significant antimetastatic activity
but no impact on primary tumor growth (24, 25).
In this study, we examined the bioactivity of IL-15cx to CD8
T cells and explored whether T-bet was involved in IL-15cx
driving CD8 T cell expansion. Antitumor activity of IL-15 was
evaluated in two murine breast cancer models, mouse Her2/neu+
and 4T1-luc mammary cancers treated with systemic
administration and intratumor delivery of plasmid IL-15/
IL-15Ra, respectively. The potential efficacy of combination
therapy with depletion of myeloid-derived suppressor cells
(MDSCs) was studied as well. In addition, immune cells
responding to IL-15cx therapy were identified to help
understand the immunobiology of antitumor activity
MATERIALS AND METHODS
Tumor Cell Lines
Mouse Her2/neu+ mammary carcinoma (MMC) was obtained
from Dr. Manjili ‘s group at Virginia Commonwealth University
who established MMC cell lines from the spontaneous mammary
tumor of Her2/neu transgenic FVBN202 mice (26). 4T1-luc
murine mammary cancer cells were originally provided by Dr.
Gary Sahagian at Tufts University (27) and maintained in high-
glucose Dulbecco’s Modified Eagle Medium (ATCC® 30–
2002™) (ATCC)-supplemented with 10% fetal bovine serum
(FBS), non-essential amino acids, and antibiotics (100 units/ml
penicillin and 100 mg/ml streptomycin) (three items above from
Atlanta Biologicals).
Reagents and Antibodies
Mouse CD4+CD25+ Treg isolation kit (Cat#130-091-041), Anti-
thy 1.2 Microbeads (Cat# 130-091-376), mouse CD8a+ T cell
isolation kit (Cat# 130-104-075) (Miltenyi Biotech); recombinant
human IL-15 (Cat#247-ILB-025), recombinant mouse IL-15Ra/
Fc chimeric protein (Cat#551-MR-100), anti-Gr-1 monoclonal
Ab (Cat#MAB1037-500) (R&D); Carboxyfluorescein
succinimidyl ester (CFSE) (Cat#87444-5MG), 5 mM in DMSO
(Sigma); low-endotoxin, azide-free anti-CD3 antibody (2C11
clone), anti-CD16/32 (Fc block) (Cat#101319), rat anti-mouse
CD8 APC Cy7 (Cat# 100714, RRID : AB_312753)), rat anti-
mouse CD4 FITC (Cat# 100406, RRID : AB_312691), rat anti-
mouse Gr-1 APC (Cat# 108412, RRID : AB_313377), and rat
anti-mouse CD11b PE (Cat# 101208, RRID : AB_312791),
hamster anti-mouse CXCR3 PE (Cat# 126505, RRID :
AB_1027656), rat anti-mouse CD44 APC (Cat# 103012, RRID :
AB_312963), rat anti-mouse CD62L PE (Cat# 104408,
RRID : AB_31309), hamster anti-mouse CD103 PE (Cat#
121406, RRID : AB_1133989), rat anti-mouse CD3 PE (Cat#
100206, RRID : AB_312663) and rat anti-mouse NKp46 PE Cy7
(Cat# 137603, RRID : AB_10552741) (Biolegend); mouse IFN-g
ELISA Set (Cat#555138) (BD biosciences) were obtained from
indicated vendors, respectively. Plasmids IL-15/IL-15Ra
expressing mouse IL-15 and IL-15Ra was provided by Drs. B.
Felber and G. Pavlakis (National Cancer Institute, Bethesda,
MD) and commercially produced by Aldevron, (Fargo, ND).
Mice
C57BL/6, T bet knock-out B6.129S6-Tbx21tm1Glm (T-bet-),
female Balb/c and parental FVB mice were purchased from
Jackson Laboratories ((Bar Harbor, ME)). Female Her2/neu
transgenic FVBN202 mice were obtained from Charles River
Laboratories (Wilmington, MA). FVBN202 mice over-express a
non-activated rat neu transgene under the regulation of the
mouse mammary tumor virus promoter (28). T-bet- mice are
lack of T-box transcription factor, TBX21 (29). C57BL/6 and
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T-bet- mice were used to study ex vivo and in vivo proliferation of
cytotoxic CD8 T cells. Female FVB and FVB202 mice were used
to establish MMC tumor model whereas female Balb/c mice were
utilized to establish 4T1-luc orthotopic breast tumor model.
Ex Vivo Proliferation of Cytotoxic T Cells
CD8 T cells isolated from C57BL/6 or T-bet mice and with purity
over 95% (Supplementary Figure 1) were labeled with CFSE
(5 µM) (30). The IL-15/IL-15Ra-Fc complex was prepared by the
incubation of IL-15 plus IL-15Ra-Fc in a ratio 1: 6 (by weight) in
PBS at 37°C for 30 min. Of note, the excess amount of IL-15Ra-
Fc was used here to block any free IL-15 in the media. CFSE
labeled CD8 T cells (2 x 105) were placed into a well of a 24-well
plate with no cytokine (control), IL-15 (1, 5 or 10 ng/ml), IL-
15Ra-Fc (6, 30, 60 ng/ml) or IL-15/IL-15Ra-Fc complex (IL-
15cx) (7, 35 or 70 ng/ml containing IL-15 and IL-15Ra-Fc at
respective concentration) and incubated at 37°C with 5% CO2 for
5 days. Cells were harvested to analyze the proliferation of T cells
by flow cytometer (Beckman-Coulter FC500). Quantification of
proliferation was determined by gating on both diluted CFSE+
cells and CD8+ T cells and determining the frequency of cells in a
total live cell gate.
The Suppression of CTL Proliferation
by Tregs
A 48-well plate was precoated with low-endotoxin/azide-free
anti-CD3 antibody at 0.5 mg/ml for overnight. Splenocytes
depleted of T cells from C57BL/6 were used as antigen
presenting cells (APC) after exposure to 10 Gy of radiation.
Natural CD4+CD25+ Tregs were isolated from lymph nodes.
2.5 × 105 CFSE-labeled CD8 T cells, 1 × 106 APC and variable
numbers of Tregs with or without IL-15 1 ng/ml were cocultured
in a 48-well plate. 3 days later, cells were stained with anti-CD8
Ab and analyzed by flow cytometer (Beckman-Coulter FC500).
Treg suppressor function was calculated: Suppressor function
(%) = [(% dividing CD8+ T cells without Tregs − % dividing CD8+
T cells with Tregs)/% dividing CD8+ T cells without Tregs] x 100.
Supernatants from this assay were collected and stored at
-80°C for further analysis of IFN-g by ELISA.
In Vivo Proliferation of Cytotoxic T Cells
CFSE labeled CD8 T cells (5 x 106 in 100 µl RPMI) isolated from
C57BL/6 or T-bet- mice were administrated intravenously via tail
vein into mice. On the same day, IL-15 (2.5 µg) or preformed IL-
15cx (12.5 µg containing 2.5 µg IL-15 and 10 µg IL-15Ra-Fc) was
given intraperitoneally (i.p.) into mice. Five days later, mice were
euthanized. Spleens and lymph nodes were harvested to assess
the proliferation and CXCR3 expression of T cells.
MMC Tumor Model and Systemic
Cytokine Treatment With or Without
Depletion of MDSCs
Female FVB parent or FVBN202 transgenic mice at 6–10 weeks of
age were injected in the left posterior mammary fat pad with 5 ×
106 neu+-MMC cells. After tumor inoculation days 5 and 10,
animals were treated with i.p. PBS (as controls), IL-15 (2.5 µg),
IL-15Ra-Fc (10 µg), or IL-15cx complex (12.5 µg) of which two
components were mixed as the same molar ratio and incubated
30 min at 37°C before treatment. To depleteMDSCs, anti-Gr-1 Ab
(100 µg) was given i.p. to the tumor bearing animals after tumor
inoculation days 4, 9, and 14. Tumor sizes were measured twice a
week by a digital caliper. The calculation of tumor volume was
described in our previous publication (31). The studies have been
reviewed and approved by the Institutional Animal Care and Use
Committee (IACUC) at Virginia Commonwealth University.
4T1-luc Breast Tumor Model and Intra-
Tumoral Gene Electrotransfer (GET)
A pilot study demonstrated that mice immunized with frozen/
thawed 4T1-luc cells resulted in no protection, thus luciferase
transgenic 4T1 cells (4T1-luc) are not immunogenic (manuscript
under preparation). 1 × 106 4T1-luc cells were inoculated in the
left posterior mammary fat pad of female Balb/c mice aged 8-10
weeks. Tumor sizes were measured twice a week by a digital
caliper. When tumor sizes reached 4 to 6 mm (equivalent to 30 ~
80 mm3), mice were anesthetized and intra-tumoral GET was
performed. The DNA plasmid pIL-15/IL-15Ra (50 µl at 2 µg/ml)
was administered directly into tumors then electric pulses were
applied by a two-plate electrode using a BTX ECM 830 pulse
generator. Pulse parameters were 5 ms, 600 V/cm, 10 pulses and
1 Hz (32). GET was performed three times at days 0, 4 and 7. The
study has been reviewed and approved by the IACUC at Old
Dominion University.
IFN-g Release From Splenocytes to
Antigen Recall and ELISA
Splenocytes (2 × 105), which were prepared from parent FVB or
FVBN202 transgenic mice with various treatments, were
incubated in a 96-well cell culture plate at 37°C for 24 h with
medium alone (control), irradiated neu- MMC or neu+ MMC
(2 × 104), respectively. Supernatants were collected to quantify
IFN-g release by ELISA following the manufacturer instructions.
A standard curve was made by six two-fold serial dilutions of the
mouse IFN-g protein (the range of concentration between 15.6–
1,000 pg/ml). The IFN-g concentrations of samples were
calculated from the standard curve. Samples were re-evaluated
with appropriate dilutions if the concentrations of samples were
out of the range of standard curve.
Flow Cytometry
All cells from ex vivo cell culture experiments, or 1 to 2 million
peripheral blood mononuclear cells (PBMCs), splenocytes or
lymphocytes were collected and suspended in 100 µl complete
media or FACS buffer (2% FBS in DPBS), then cells were added
to a single antibody or antibody mixture and incubated at 4°C for
45 min. Cells were washed with 2 ml FACS buffer twice and re-
suspended in 0.5 ml FACS buffer with 2.5% paraformaltehyde for
flow cytometric analysis by FACSAria (BD Biosciences) or
MACSQuant® Analyzer 10 (Miltenyi Biotec). To analyze
effector/memory T cells in blood, spleen and lymph nodes,
CD3+CD4+ or CD3+CD8+ cells were gated for the analysis of
CD44 and CD62L expression on these double positive cells.
Guo et al. IL-15 Receptor Complex for Breast Cancer
Frontiers in Immunology | www.frontiersin.org February 2021 | Volume 11 | Article 6146673
Statistical Analysis
All values from experimental groups were reported as the mean ±
standard deviation (SD) or standard error (SE) indicated in
Figure legends, respectively. Animals were grouped randomly
based on tumor sizes before treatments. Experiments in this
study generated quantitative changes of immune cells and their
function including CD8+ T cells, CXCR3+ CD8+ T cells, CD4+ T
cells, CD44+CD62+/CD44+CD62- central/effector memory T
cells, CD8+CD103+ tissue resident memory T cells,
CD3+NKp46+ NKT cells, CD11b+Gr-1+ MDSCs, the
suppressor function of Tregs, the IFN-g production and tumor
sizes. Analysis of these quantitative data were performed by One
Way ANOVA for multiple groups or t-test for two groups. If One
Way ANOVA showed statistical significance, then Pairwise
Multiple Comparison Procedures (Holm-Sidak method) were
done to compare various pairs of groups. Animal survival was
analyzed with Log-Rank test. Statistical significance is assumed at
p < 0.05. All statistical analysis was completed using the
SigmaPlot 12.0 (Systat Software, Inc., San Jose, CA,
RRID: SCR_003210).
RESULTS
IL-15cx Shows Superior Bioactivity to
Expand CD8 T Cells In Vivo in Comparison
to an Equimolar Single Chain IL-15
First, we examined if IL-15 or IL-15cx we purchased could
promote the expansion of CD8 T cells ex vivo and in vivo.
Regardless of the presence of APCs either soluble IL-15 or IL-
15cx alone in cell culture was insufficient to drive naïve CD8 T
cells into cell-division cycle (Supplementary Figure 2A).
However, IL-15 or IL-15cx in the media greatly prevented cell
death of CD8 T cells. In contrast, almost all cells underwent cell
death while there was IL-15Ra alone or in the absence of
cytokines. A similar phenomenon was seen when IL-7 was
added to the media instead of IL-15 (Supplementary Figure
3). Noticeably, the combination of IL-7 with IL-15 or IL-15cx
was able to drive a small percentage of T cells into cell cycle
resulting in a moderate proliferation with 3-4 cell divisions in 5
days. Nevertheless, after intraperitoneal administration of IL-
15cx CD8 T cells from both spleens and lymph nodes showed a
large expansion with at least 6-7 divisions of proliferation in 5
days (Supplementary Figure 2B). Contrastingly, the same molar
amount of IL-15 was inefficient to promote CD8 T cell
proliferation in vivo.
The Absence of T-Bet Diminishes the
Capacity of CD8 T Cell Proliferation Due to
IL-15 or IL-15cx
T-bet plays a critical role in the CD8 T cell proliferation and
differentiation by IL-12 (33), and the fate of effector and
memory CD8 T cells (34, 35). However, the impact of T-bet
on the IL-15-mediated naïve CD8 T cell proliferation is
unclear. To investigate if T-bet participates in naïve CD8 T
cell proliferation by IL-15, CD8 T cells isolated from T-bet-
mice were used to assess the bioactivity of IL-15 ex vivo and in
vivo. Since IL-15 alone is inefficient for proliferation of CD8 T
cells ex vivo, the precoated anti-CD3 antibody (aCD3) was
added in cell culture. Both wild-type and T-bet− CD8 T cells
greatly responded to aCD3 initiated proliferation (Figure 1A).
Lack of T-bet reduced T cell expansion by 11% (p = 0.029)
(Figure 1B). The addition of IL-15 was able to further enhance
the aCD3 elicited expansion by approximately 5% in both
wild-type and T-bet- CD8 T cells. However, lack of T-bet
appeared to increase the variation of cell proliferation in
response to aCD3 with or without IL-15 which led to no
statistical significance in T-bet- cells (p = 0.362) comparing to a
significant change in wild-type T cells (p = 0.047). We then
evaluated the impact of T-bet on the proliferation of CD8 T
cells in vivo by IL-15cx. As shown in Figures 1C, D, T-bet-
CD8 T cells were able to expand but with a 30% reduction in
cell frequency than wild-type CD8 T cells (p = 0.035).
However, there was essentially no difference in the
upregulation of CXCR3, an important chemokine receptor
for T cell function, between wild-type and T-bet- CD8 T
cells. A small (9~11%) but significant decrease of CXCR3+
cells was nonetheless observed in CD8 T cells from lymph
nodes in contrast to splenic CD8 T cells regardless of their T-
bet status.
IL-15 Antagonizes the Suppression of
Tregs to Cytotoxic T Cell Proliferation and
IFN-g Release
Tregs are present in the tumor microenvironment of breast
cancer and are associated with unfavorable prognosis (36). Dr.
Cerf-Bensussan’s group (37) reported that IL-15 impeded the
suppressor function of human CD4+CD25+ Tregs to autologous
CD4 or CD8 T cells. To examine if this is also true in mice,
CD44hi CD8+ T cells were isolated to carry out the Treg
suppression assay. As seen in Figure 2A, natural Tregs showed
a potent suppressor function to the proliferation of CD44hiCD8+
effector/memory-like T cells by aCD3 stimulation in a dose
dependent manner. In the presence of IL-15, the suppressor
function was reduced by 9.1%, 14.2%, 29.5%, and 35.9%,
respectively with effector T cells versus (vs) Tregs at ratios 1:1,
2:1, 4:1, and 8:1 (Figure 2B). Of note, the reversal of IFN-g
release from memory-like T cells was more pronounced than the
cell expansion (Figure 2C). The increase of IFN-g production by
IL-15 was correlated with the Tregs vs effector ratio as well.
Without IL-15, IFN-g release was severely suppressed by Tregs
even at a high ratio of effector T cells versus Tregs, which
indicates the cytotoxic function of memory CD8 T cells was
impaired. At low ratios of effector T cells vs Tregs (2:1 or 1:1)
there was no obvious IFN-g release by CD8 T cells even when
these cells exhibited visible proliferation. At an effector vs Treg
8:1 ratio, the IFN-g production was decreased by 77% with a
reduction of 45% cell proliferation. However, in the presence of
IL-15 (1 ng/ml) the IFN-g release was completely recovered to
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the level of memory cells without the suppression of Tregs.
Noticeably, cell proliferation was still below the level of no Treg
control. This phenomenon of IFN-g release outpaced cell
proliferation suggests IL-15 either impedes the suppressor
function of Tregs or renders memory T cells more resistant to
the Treg suppression.
Intraperitoneal IL-15cx Results in Breast
Cancer Growth Inhibition Associated With
CTL Amplification and MDSC Reduction
To evaluate the therapeutic efficacy of IL-15cx for breast cancer,
neu+-MMC tumors were initiated in Her2/Neu transgenic
female FVBN202 mice or parent FVB mice. As seen in Figure
3A, neu+-MMC tumors fluctuated to grow in FVB mice in
contrast to rapid growth in transgenic FVBN202 mice. Seven
days after the first dose of IL-15cx treatment tumor growth was
slower than that in control mice. This growth inhibition by IL-
15cx therapy was maintained till the endpoint or euthanasia of
animals. Nevertheless, no complete tumor regression was
observed among the 8 mice treated with IL-15cx. On the other
hand, IL-15 (Figure 3A) or IL-15Ra-Fc (Data not shown)
treatment did not show any significant tumor growth
inhibition. Animals were euthanized at the endpoint, and
blood and spleens were collected to examine changes in
CD11b+Gr1+ MDSCs, T cells and IFN-g release after re-
stimulation with tumor antigens. CD8+ T cells in spleen were
significantly higher in the IL-15cx treated tumor mice than in
control or the IL-15 treated tumor mice (Figure 3B). Although
CD4+ T cells increased approximately 30% in both IL-15 and IL-
15cx treated mice compared to control tumor mice, the
difference was not statistically significant (Figure 3C). There
was a dramatic 6 ~ 18-fold increase of IFN-g release from the IL-
15cx treated splenocytes incubated with irradiated neu+ or neu-
-MMC cells in comparison with control, FVB, IL-15, or IL-15Ra
treated splenocytes (Figure 3D).
The increase of MDSCs is associated with tumor burden in
breast cancer patients (38) and mouse mammary cancer models
(39, 40). Consistent with literature reports, MDSCs were
remarkably escalated in both blood and spleen of tumor mice
(Figures 3E, F). The treatment with IL-15cx was able to greatly
decrease the frequency of MDSCs in both blood and spleen
whereas IL-15 treatment significantly reduced MDSCs in the
spleen but had a less pronounced impact on these cells in the
blood. Of note, the frequencies of MDSCs in blood or spleen in
IL-15 treated animals were still six- to eight-fold higher than
those in FVB mice.
A B
C D
FIGURE 1 | The impact of T-bet on CD8 T cell proliferation by interleukin 15 (IL-15) or IL-15cx. (A, B) T-bet influenced ex vivo CD8 T cell proliferation with or without
IL-15. Unfractionated naïve CD8 T cells from C57BL/6 or T-bet- mice were labeled with CFSE (5 µM) and then incubated with irradiated antigen presenting cells and
aCD3 (0.5 mg/ml) with or without IL-15 (1 ng/ml). Three days later, cells were analyzed by flow cytometry. (A), Flow cytometric analysis of one representative
experiment from four independent experiments. (B) Percentages of dividing (diluted CFSE) CD8 T cells in total gated live cells (n = 4). (C, D) T-bet was involved in in
vivo CD8 T cell proliferation by IL-15cx. Unfractionated naïve CD8 T cells from C57BL/6 or T-bet- mice were labeled with CFSE (5 µM) and then injected into tail
veins of naïve C57BL/6 mice. Five days later, animals were euthanized, and tissue collection and analysis were carried out. (C) Flow cytometric analysis of one
representative mouse from three mice. (D) Percentages of dividing (diluted CFSE) CD8 T cells in total gated live cells and Percentages of CXCR3+ cells in total CD8+
T cells (n = 3). Error bars represent standard deviations. *p < 0.05 and **p < 0.01 by One Way ANOVA.
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The Depletion of MDSCs Has No Effect On
Mammary Cancer Growth and Therapeutic
Efficacy of IL-15cx
An overwhelming number of MDSCs are present in mice with
tumors, and the levels of these suppressor cells are still much
higher in tumor bearing transgenic mice treated IL-15 or IL-15cx
than parent FVB mice (Figures 3E, F). This made us question
whether further removal of excessive MDSCs could slow tumor
growth and enhance the antitumor activity of IL-15cx.
Surprisingly, the depletion of MDSCs with anti-Gr-1 antibody
had no impact on the tumor growth in control mice (Figure 4A)
althoughMDSCs in blood were brought down from 53% in control
mice to the same level (5%) in FVB mice (Figures 4B, C).
And interestingly, the administration of IL-15cx made MDSCs
resistant to the cytotoxicity of anti-Gr-1 antibody. The frequency
(~26%) of MDSCs in the blood of mice treated with both IL-15cx
and anti-Gr-1 antibody maintained the same level (~24%) in
animals treated with IL-15cx alone. Regardless of the MDSC
depletion status, anti-Gr-1 antibody failed to increase CD8 T
cells in both control and IL-15cx treated animals (Figures 4B, D).
Unfortunately, no complete tumor regression was achieved in
mice treated with IL-15, IL-15cx with or without the depletion of
MDSCs. All mice were euthanized due to primary tumor growth
having reached the endpoints in the approved IACUC protocol.
Therefore, long-term antitumor immunity could not be assessed
for the systemic treatment with IL-15 or IL-15cx.
Intratumoral GET With Plasmid IL-15/IL-
15Ra Results in a Survival Benefit for
Mammary Carcinoma Bearing Mice Which
Is Associated With an Early Increase of
Local Cytotoxic Cells and Long-Term
Memory T Cells Resulting From Complete
Tumor Regression
The delivery of plasmid IL-15 by GET into tumor tissue led to the
regression of B16 melanoma in mice (41), hence we investigated
if this strategy could benefit breast cancer bearing animals. GET
with plasmid IL-15/IL-15Ra did result in 4T1-luc tumor growth
inhibition or regression (p = 0.008–0.038 between Ctrl and GET
groups during days 10–24 in Figure 5A). Importantly, 25% (2/8)
of animals obtained complete tumor regression and remained
tumor free following GET with plasmid IL-15/IL-15Ra.
Noticeably, blood drawn from these two mice that were tumor
free over 3 months exhibited an increase of memory T cells
including effector/central memory CD8+ and central memory
CD4+ T cells compared to control tumor mice (Figure 5B). To
explore what types of cells likely responded to intratumor GET
treatment, 2 days after the completion of GET treatment, animals
were euthanized to analyze immune cells in draining lymph
nodes, blood and spleen. GET treatment had no impact on
MDSCs (Figure 5C), Tregs and NK cells (data not shown) in
blood and spleen but did increase CD8+CD103+ tissue resident T
cells by 25% (p = 0.058) and CD3+NKp46+ NKT cells by 66%
A
B C
FIGURE 2 | Interleukin 15 (IL-15) antagonized the suppression of Tregs to CD8 T cell proliferation and cytotoxic function. CD44hiCD8 T cells from C57BL/6 mice
were labeled with CFSE (5 µM) and then incubated with irradiated antigen presenting cells, aCD3 (0.5 mg/ml), and natural Tregs at various ratios (of Tregs vs CD8 T
cells indicated in the Figure) with or without IL-15 (1 ng/ml). Three days later, cells were analyzed by flow cytometry. (A) Flow cytometric analysis of one
representative experiment from four independent experiments. The absolute numbers and percentages of dividing CD8 T cells in total gated live cells were indicated.
(B) IL-15 diminished the suppressor function of Tregs to CD8 T cell proliferation. The suppressor function of Tregs was normalized by CD8 T cell proliferation without
the presence of Tregs (n = 4 independent experiments). (C) IL-15 promoted cytotoxic CD8 T cell function under the presence of Tregs. Supernatants collected from
(B) were used to measure IFN-g production by ELISA. Error bars represent standard errors (B) or standard deviations (C). *p < 0.05, **p < 0.01 and ***p < 0.001 by
t-test.
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(p < 0.001) (Figure 5C) in draining lymph nodes. There was a
heterogeneous but insignificant change of T cells in spleen and
blood (Supplementary Figure 4). While one of five treated mice
showed a threefold increase in T cells in the spleen and two mice
exhibited a 40-60% increase, there was no apparent increase in
the other two GET treated mice. These preliminary data suggest
a distinct mechanism of intratumoral GET that initially
promotes local antitumor immunity versus systemic
enhancement of T cell proliferation and function by IL-15cx.
The two mice treated with GET and were long-term tumor
free were challenged with live 4T1-luc cells. Both animals
rejected breast tumor growth. This result is in line with
increases of memory T cells (Figure 5B) further suggests
long-lasting immunity can be induced by intratumoral
GET treatment.
DISCUSSION
IL-15 as a monotherapy for solid tumors is not as effective as
expected (42). Two major strategies including IL-15 superagonist
and combination therapy have been pursued to improve its
therapeutic efficacy. A number of studies have demonstrated
the advantages of IL-15 superagonist over free monomeric IL-15,
such as a longer half-life (20, 23, 43), better in vivo expansion of
cytotoxic T/NK cells, and higher antitumor activity (22–24). We
report here preformed IL-15cx can significantly expand CD8 T
cells in vivo. T-bet apparently plays a certain, but not major,
role in IL-15 driving T cell proliferation whereas CXCR3
upregulation by IL-15cx is independent of T-bet. Two doses of
systemic IL-15cx showed a moderate antitumor activity for
mouse breast cancer, which is likely associated with the
promotion of cytotoxic T cell expansion and function
enhancement. However, a successful depletion of MDSCs does
not convert to any therapeutic benefits. We have also found IL-
15cx antagonizes the depletion of MDSCs. Importantly, a
significant antitumor activity including long-term complete
tumor regression has been shown in animals treated with
intratumoral delivery of IL-15/IL-15Ra co-expressing DNA.
Further analysis indicates that the promotion of regional
cytotoxic T cells is potentially involved in antitumor immunity.
IL-15 alone is able to induce a strong amplification of CD44hi
memory phenotype CD8 T cells both in vitro and in vivo but
hardly stimulates the proliferation of CD44low naïve CD8+ T cells
(44). However, when examining unfractionated CD8 T cells in
our study, few cells were found to be driven by IL-15 into one-to-
two cell divisions then halted, both in vitro and in vivo. Our in
vitro results can be explained when a very low concentration of
IL-15 [here 1 ~ 10 ng/ml vs 10 ~ 1,000 ng/ml (44)] is used.
Though comparable in vivo doses of IL-15 [here 2.5 µg vs 1 ~ 4
A B C
D E F
FIGURE 3 | A moderate tumor growth inhibition by systemic administration of interleukin 15 (IL-15) was associated with the promotion of CD8 T cells and antitumor
specific immunity and the reduction of myeloid-derived suppressor cells (MDSCs). Breast tumors were established by injections of 5 × 106 neu+-MMC cells in the left
posterior mammary fat pad of parent female FVB mice (FVB, n = 7) or Her2/neu transgenic FVBN202 mice. After tumor inoculation days 5 and 10 (indicated by
arrows), tumor-bearing FVBN202 mice were treated with i.p. PBS as controls (Ctrl, n = 10), IL-15 2.5 µg (IL-15, n = 8), IL-15Ra-Fc 10 µg (IL-15R, n = 5), or
equimolar IL-15cx (IL-15cx, n = 8). (A) Growth curves of neu+-MMC breast tumors. (B–F) Animals were euthanized at day 28. Blood and spleens were collected
from three mice per group to examine immune cells or their function. (B) Percentages of CD8+ T cells in total gated live splenocytes. (C) Percentages of CD4+ T cells
in total gated live splenocytes. (D) IFN-g release from splenocytes cocultured with medium, irradiated neu–MMC or neu+-MMC for 24 h. No tumor-bearing FVBN202
mice were used as naïve mice control (Naive). (E) Percentages of CD11b+Gr-1+ MDSCs in total gated live splenocytes. (F) Percentages of CD11b+Gr-1+ MDSCs in
total gated peripheral blood mononuclear cells (PBMCs). Error bars represent standard errors (A) or standard deviations (B–F). *p < 0.05, **p < 0.01, and
***p < 0.001 by One Way ANOVA. p values between two groups were indicated (B, C, E, F). If not indicated (A, D), it means significant to all other groups.
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µg/mouse (44)] were adopted in both studies, a significant
portion of CD8 T cells were found proliferating as indicated by
BrdU positive cells in Dr. Zhang’s report (44). Nevertheless,
other groups (20, 23) reported inefficient proliferation with a
comparable dose of IL-15 when a CFSE labeling approach was
employed. Therefore, the disparity is likely due to two distinct
methods; otherwise, it suggests BrdU incorporation is more
sensitive than CFSE labeling at measuring cell stimulation.
The JAK1/3 and STAT3/5 signaling pathways are utilized by
IL-15 for T cell activation (8, 45), and T-bet is a known essential
regulator of T cell differentiation and function (46). Although T-
bet has been demonstrated as a critical factor for antigen-specific
CD8 T cell function development (33), according to Dr.
Glimcher’s report, it plays an insignificant role in cell
proliferation from antigen-driven activation or aCD3/CD28
stimulation (47). However, our data showed that T-bet is
partially involved in aCD3-induced ex vivo (Figures 1A, B)
and IL-15cx-initiated in vivo (Figures 1C, D) naïve CD8 T cell
proliferation. Noticeably, T-bet- and wild-type OT-I TCR CD8
T cells were examined in above mentioned Dr. Glimcher’s
study. The different source of CD8 T cells could explain
this discordance which can be validated by well-designed
experiments. Undoubtedly, TCR engagement or aCD3
signaling is a major driver of naïve CD8 T cell stimulation;
whereas, IL-15 signaling appears more important in the
generation and reactivation of memory-like CD8 T cells (44,
48–50). We have noticed that T-bet has a greater impact on the
CD8 T cell proliferation in vivo than ex vivo due to IL-15 or IL-
15cx. T-bet is a key regulator for Th1 cytokines (IL-12/IFN-g)
which promote CD8 T cell proliferation. Therefore, the
deficiency of T-bet likely diminishes the response of CD8 T
cells to Th1 cytokines in vivo in lymphoid tissues, including
spleen and lymph nodes.
Both CD8 T cells and NK cells have been deemed necessary
for IL-15cx or the superagonist to mediate antitumor immunity
(24). However, in some circumstances, if NK1.1 cells become a
major responder, the long term immunity or immune memory
cannot be established (51). The importance of CD8 T cells has
also been elaborated by Dr. Knudson’s group whereby the
tumor-resident, rather than newly infiltrating CD8 T cells,
were found to be responsible for the destruction of mouse
melanoma (22). Our study is consistent with these literature
findings. Partial tumor regression is only seen in mice treated
with IL-15cx with a significant increase of CD8 T cells. On the
other hand, no antitumor activity was observed in animals
treated with IL-15 (Figure 3) or anti-Gr-1 alone, whereby the
findings are associated with a depletion of MDSCs and no
increase in CD8 T cells (Figure 4). In addition to expansion of
A B
C D
FIGURE 4 | No therapeutic effect of the myeloid-derived suppressor cell (MDSC) depletion on mammary tumor growth and IL-15cx treatment. Breast tumors were
established by injections of 2.5 × 106 neu+-MMC cells in the left posterior mammary fat pad of parent female FVB mice (FVB, n = 4) or Her2/neu transgenic
FVBN202 mice. Tumor-bearing FVBN202 mice were treated with i.p. PBS as controls (Ctrl, n = 4), anti-Gr-1 Ab 100 µg (aGr-1, n = 4), IL-15cx 12.5 µg (IL-15cx, n =
4), or both anti-Gr-1 Ab and IL-15cx (IL-15cx+aGr-1) (n = 4). Anti-Gr-1 Ab was given i.p. at days 4, 9, and 14 (indicated by red arrows) while IL-15cx was
administrated i.p. at days 5 and 10 (indicated by black arrows). (A) Growth curves of neu+-MMC breast tumors. (B–D) Blood was collected via tail vein bleeding from
three mice per group to examine immune cells. p values mean Ctrl or aGr-1 vs IL-15cx or IL-15cx+ aGr-1. (B) Flow cytometric analysis of one representative mouse
from three mice. The percentages of CD8+ T cells or CD11b+Gr-1+ MDSCs in total gated live peripheral blood mononuclear cells (PBMCs) were indicated.
(C) Percentages of CD11b+Gr-1+ MDSCs in total gated live PBMCs. (D) Percentages of CD8+ cells in total gated live PBMCs. Error bars represent standard
deviations. *p < 0.05, **p<0.01, and ***p < 0.001 by one-way ANOVA.
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existing antigen specific CD8 T cells, our ex vivo functional
assays of Tregs suggest IL-15cx likely enhances the function of
CD8 T cells as well (Figure 2). Interestingly, a dramatic release of
IFN-g from splenocytes in response to tumor antigens is
discovered in IL-15cx treated mice but not in parental FVB
mice with spontaneous rejection of neu+-MMC (Figure 3). This
finding suggests a different antitumor mechanism involved
between transgenic or non-neu transgenic FVB mice. The fact
that splenocytes responded to both neu+ and neu–MMC
indicates antitumor immunity is not dependent on HER2,
oncoprotein but rather on other tumor specific or
associated antigens.
Despite very potent bioactivity of IL-15 or IL-15cx at
promoting cytotoxic T/NK cells, IL-15 immunotherapy
appears ineffective at destroying poorly immunogenic primary
tumors such as breast cancer. Both Drs. Kim (24) and Knudson
(25) reported that an IL-15 superagonist ALT-803 had no impact
on primary 4T1 breast tumor but could prolong animal survival
if the primary tumor was removed by surgery. The survival
benefit comes from the reduction/elimination of disseminated
tumor cells or antimetastatic effect. Ineffective eradication of
primary tumor is likely because of (1) immune suppressive
tumor microenvironment of 4T1 breast tumor (31), (2) T cell
exhaustion (51) and (3) lack of tumor resident memory T cells
(22). Here we have examined a different strategy of IL-15
immunotherapy, intratumoral GET, in a 4T1 breast cancer
model. Though there is no notable and uniform increase/
decrease of circulating T, NK cells, Tregs or MDSCs, a
significant tumor regression and survival benefit has been
achieved while regional cytotoxic cells greatly rise (Figure 5).
Our discovery, together with above mentioned reports,
emphasize the importance of local immunotherapy with IL-15
or IL-15cx to elicit effective antitumor immunity for a poorly
immunogenic tumor or “cold” tumor.
Combination immunotherapy has been proposed to enhance
the efficacy of IL-15 (42). MDSCs are predominant in 4T1 breast
tumor and have been reported to associate with tumor burden
or late stage breast tumor (38). MDSCs have been suggested as a
target for the enhancement of immunotherapy and shown an
improved immunity of cancer vaccine in mouse and human
lung cancer (52, 53). However, our data appears to disagree with
this approach for the 4T1 model and IL-15 immunotherapy.
The depletion of MDSCs does not change the growth pattern of
4T1 tumor. It is probably other immune suppressive cells such
as Tregs and tumor associated macrophages taking over or
compensating for the immunosuppression of MDSCs. We
have found that the depleting antibody loses its efficacy when
IL-15cx is present (Figure 4). This result is consistent with the
promotion of CD11b+ myeloid cells by IL-15 (54, 55). However,
in our study IL-15 or IL-15cx treatment has been shown to
decrease MDSCs in tumor mice (Figure 4). Taken together, the
impact of IL-15cx on MDSCs is complicated and needs further
investigation to understand its contribution to the
antitumor activity.
We would like to point out there are some limitations of this
research. Metastatic diseases including organ metastasis and
A
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FIGURE 5 | Therapeutic effect of intratumoral gene electrotransfer (GET) with plasmid interleukin 15 (IL-15)/IL-15Ra in breast tumor. Breast tumors were established
by injections of 1 × 106 4T1-luc cells in the left posterior mammary fat pad of female Balb/c mice. Tumors (30–80 mm3) were treated with intratumoral saline (Ctrl,
n = 10) or plasmid DNA IL-15/IL-15Ra (GET, n = 8) with electrical pulse deliveries at days 0, 4, and 7 (indicated by arrows). (A) Growth curves of 4T1-luc breast
tumors and survival curves of tumor bearing animals. *s p = 0.008–0.038 between Ctrl and GET groups during days 10–24 by t-test. *p < 0.05 between Ctrl and
GET treatment by Log-Rank test. (B) Percentages of memory CD8/CD4 T cells in PBMCs. Flow cytometric analysis was performed at day 15 for tumor mice (Ctrl,
n = 3) or day 107 for long-term tumor free mice after GET treatment (GET, n = 2). (C) Systemic and regional changes of immune cells after GET. Two days after the
completion of GET treatment, animals (n = 5) were euthanized to analyze MDSCs in blood and spleens, and CD103+CD8+ tissue resident memory cells and
Nkp46+CD3+ NKT cells in draining lymph nodes. Error bars represent standard deviations. $p = 0.074, #p = 0.058, *p < 0.05 and ***p < 0.001 by t-test.
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circulating tumor cells are not evaluated. It is possible that
systemic or local delivery of IL-15/IL-15cx could reduce
metastatic burdens as reported by Drs. Kim and Knudson (24,
25), in which primary tumor should be removed after the
treatment has been done. In terms of mechanisms of IL-15cx
therapy, CD8 T cells are emphasized in this study. Other cells,
such as NK and NKT cells that can respond to IL-15cx as well,
should be investigated to gain a better picture of immune
response. Our limited data suggest that increases of regional
tissue resident memory T and NKT cells are associated with
effectiveness of IL-15cx therapy. Further analysis of dynamic
changes of immune cells in tumor microenvironment should
help us understand the different mechanisms in terms of local vs
systemic IL-15cx treatment or effective vs ineffective IL-15cx
treatment. Our future research is to enhance the efficacy of IL-
15cx treatment and elucidate the mechanisms of heterogeneous
immune outcomes.
In conclusion, our study demonstrated the therapeutic
potent ia l of IL-15cx as a potent ia l breas t cancer
immunotherapy. We discovered that T-bet played a certain
role in IL-15cx driving CD8 T cell proliferation. Systemic
administration of IL-15cx resulted in a moderate antitumor
activity in the mouse breast tumor model though a remarkable
increase of CD8 T cell expansion and antitumor cytotoxic
function was observed. Notably, intratumoral GET with
plasmid IL-15/IL-15Ra exhibited a significant tumor
regression and survival benefit even though significant changes
of systemic cytotoxic cells and immunosuppressor cells were not
observed initially. It appears early increases of regional cytotoxic
cells were critical to the antitumor activity of GET treatment. In
addition, we demonstrated the depletion of MDSCs was
ineffective to treat mouse breast cancer. Therefore, our
research proposed local delivery with IL-15cx should be
further optimized and considered for breast cancer
immunotherapy. More effective IL-15cx based combination
therapies should be explored as well.
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